Danish Biotech Weekly – Week 27

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

The past week was eventful for the Danish biotech stocks. Genmab and Curasight posted positive phase II results, while others announced partnerships and acquisitions. However, overall the Danish biotech stocks declined. Even the share prices of the companies with positive news didn’t change much.

Only 7 of the 20 listed, Danish biotech companies published news the past week. 6 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year.

Company news the past week

Ascendis Pharma

No news the past week


No news the past week


Cessatech and Ventis Pharma announce US partnership for CT001 (Link)

CS Medica

No news the past week


Positive results in uPAR-PET/MR Phase II study in brain cancer (Link)

Evaxion Biotech

No news the past week


Phase III topline results announced for the COVID-19 booster vaccine candidate (Link)


No news the past week


Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (Link)


Gubra acquires research service provider MiniGut ApS (Link)

Gubra launches share buy-back programme to hedge incentive scheme obligations (Link)

Initiator Pharma

Initiator Pharma completes recruitment in Phase IIb trial with pudafensine (IP2015) (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency (Link)

Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech stocks delivered a negative share price performance last week of -1.7%. In the past week, Evaxion Biotech became the best performing stock with an 8% increase. Cessatech, Curasight, Evaxion Biotech, Genmab, and Gubra announced partnerships, acquisitions and study results. However, the news did not have a big effect on the companies’ share price. Saniona, on the other hand, became the worst performing Danish biotech stock for the second week in a row with a 10% decrease without any company specific news. This should be seen in light of the fact that the stock has already risen 150% this year. Other major performers year-to-date include Curasight A/S and Fluoguide A/S after soaring 120-134%.

Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.9%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.